Target Price | $100.98 |
Price | $95.93 |
Potential |
5.26%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2026 .
The average ANI Pharmaceuticals, Inc. target price is $100.98.
This is
5.26%
register free of charge
$126.00
31.35%
register free of charge
$77.77
18.93%
register free of charge
|
|
A rating was issued by 14 analysts: 12 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2026 of
5.26%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 614.38 | 856.21 |
26.20% | 39.36% | |
EBITDA Margin | 11.49% | 24.07% |
48.17% | 109.55% | |
Net Margin | -3.28% | 18.71% |
203.14% | 670.47% |
10 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2025. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.04 | 7.37 |
222.35% | 808.65% | |
P/E | 13.01 | |
EV/Sales | 2.90 |
10 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | May 12 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 17 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 08 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 11 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
May 12 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Apr 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.